The drugmaker reported that the US drug regulator has issued an establishment inspection report (EIR) for the Bileshwarpura facility in Gujarat stating that the inspection will be closed.
The US Food and Drug Administration (USFDA) conducted a pre-approval inspection at Torrent Pharma's oral oncology manufacturing facility located at Bileshwarpura in Gujarat from December 5, 2023 to December 11, 2023.
On December 12, the firm stated that the USFDA had issued a Form 483 with 5 procedural observations, post-inspection. No observations related to data integrity were reported, the company stated.
Torrent Pharma has now reported that the USFDA has issued an EIR for the Bileshwarpura manufacturing facility and the USFDA has successfully closed the inspection.
Torrent Pharmaceuticals is the flagship company of the Torrent Group. It ranks sixth in the Indian pharmaceutical market and is among the top five in the therapeutic segments of cardiovascular (CV), gastrointestinal (GI), central nervous system (CNS), nutritional vitamin minerals (VMN) and cosmodermatology.
Company's consolidated net profit rose 51.71% to Rs 443 crore and 9.67% increase in operating income to Rs 2,732 crore in Q3FY24 over Q3FY24 prosecutor 23.
The bond rose 0.11% and is currently trading at Rs 2,659.20 on the BSE.
Powered by Capital Markets - Live News
Disclaimer: No Business Standard journalists were involved in the creation of this content.
First published: March 6, 2024 | 11:16 am IS
